Electric Fields therapy in patients with glioblastoma: Long-term survival results in Germany in routine clinical care (TIGER) study.

Electric Fields therapy has demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) when applied with adjuvant CAS 85622-93-1 compared to CAS 85622-93-1 alone in newly diagnosed glioblastoma (ndGBM). Electric Fields therapy delivers electric fields, through scalp-placed arrays, that disrupt cellular processes critical for cancer cell viability, is CE marked for WHO grade 4 glioma, and is a recommended treatment regimen for ndGBM. Electric Fields  therapy was administered to >25,000 patients, showing no systemic toxicities and mild to moderate skin reactions being the main therapy-related adverse event. Here, the report survival and safety data from the TIGER study, the largest prospective study investigating real-world use of TTFields therapy during routine clinical care in patients with ndGBM in Germany.